PerkinElmer Acquires Vanadis Diagnostics, AB
Gains Innovative NIPT Solution in Development to Expand Maternal Fetal Health Portfolio
January 26, 2016 08:00 AM Eastern Standard Time
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that it has completed the acquisition of Vanadis Diagnostics, AB. Based in Sweden, Vanadis is developing a novel solution for non-invasive prenatal testing (NIPT) based on digital analysis of cell-free DNA.
"We founded Vanadis with the mission to make NIPT available to all women, and we developed this technology to fundamentally change the cost structure and workflow for NIPT"
The acquisition is anticipated to build upon PerkinElmer's maternal fetal health offerings, which provide customers a full portfolio of traditional serum screening solutions. The Vanadis platform will enable PerkinElmer to offer a simplified, cost-effective, high-throughput approach to NIPT to help facilitate wider access for pregnant women.
Many traditional biochemistry prenatal testing labs have encountered challenges in successfully implementing NIPT due to the complexity of the tests. This has led to limited acceptance of the existing NIPT technology, which has been adopted mainly by genetic laboratories. The Vanadis offering is based on digital DNA analysis and is designed to provide automated testing for routine use by high-throughput biochemistry labs as well as genetic labs.
"While NIPT is becoming increasingly recognized as valuable to many high-risk expectant parents during the first trimester, test complexity and pricing issues have limited the ability of many biochemistry labs to effectively offer this type of prenatal screening," said Prahlad Singh, President, Diagnostics, PerkinElmer. "High capital investment, advanced molecular skills, and complex data handling for lab staff, along with the difficulty of integrating these systems into the existing screening infrastructure, have been barriers to more widespread adoption of NIPT. Vanadis' simplified NIPT platform, once available, should help overcome these obstacles, giving labs a wider range of prenatal testing capabilities and providing important information to physicians and patients."
Adding Vanadis' capabilities to PerkinElmer's extensive diagnostics portfolio is intended to contribute to better health outcomes through improved detection of fetal chromosomal abnormalities. PerkinElmer's diagnostic offerings include: prenatal, neonatal and infectious disease screening, along with molecular diagnostics solutions, through its wide range of instruments, reagents and assay platforms, and software. The Company also provides private cord blood and cord tissue preservation to families through ViaCord LLC.
"We founded Vanadis with the mission to make NIPT available to all women, and we developed this technology to fundamentally change the cost structure and workflow for NIPT," said Olle Ericsson, CEO, Vanadis Diagnostics. "We are confident that with its leading position in prenatal screening, PerkinElmer is best situated to bring this system to market and address the under-served segment of average-risk pregnancies."
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2.2 billion in 2014, has approximately 8,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) our ability to obtain future financing; (19) restrictions in our credit agreements; (20) our ability to realize the full value of our intangible assets; (21) significant fluctuations in our stock price; (22) reduction or elimination of dividends on our common stock; and (23) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Tommy J. Thomas, 781-663-5889
Brian Willinsky, 781-663-5728